FDA Clears SPRINT Peripheral Nerve Stimulation System for Acute, Chronic Pain

Source: Spr Therapeutics

The FDA has cleared the SPRINT Peripheral Nerve Stimulation (PNS) System, maker SPR Therapeutics announced.

SPRINT is a minimally invasive, nonopioid, PNS system designed to provide relief for acute and chronic pain, according to SPR Therapeutics. The system consists of a threadlike lead and a matchbox-sized wearable stimulator. The lead is placed percutaneously with a fine needle, and electrical stimulation is delivered through the lead to activate the peripheral nerves to achieve pain relief.

The SPRINT system simplifies the lead placement procedure and allows physicians to target specific fibers: Lead placement can be as far as 3 cm from the targeted nerve, according to the manufacturer.

“SPRINT brings the benefits of PNS to physicians seeking safe and effective alternatives to opioids in the treatment of chronic and acute pain,” said Peter Staats, MD, MBA, an immediate past president of the American Society of Interventional Pain Physicians, in a press release. “Unlike all other PNS systems, SPRINT does not require permanent implantation, which should reduce invasiveness, risk and cost.”

The system is designed to be withdrawn without surgery at the end of the 30-day treatment period, according to SPR Therapeutics.

—PMN Staff

Based on a press release from SPR Therapeutics.